Verastem (VSTM) Equity Average (2012 - 2026)
Verastem's quarterly Equity Average came in at $69.5 million in Q1 2026, up 326.62% year-on-year from $16.3 million in Q1 2025, and up 233.5% quarter-over-quarter from $20.8 million in Q4 2025.
Verastem has reported Equity Average for 15 years, with the latest figure at $69.5 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average rose 326.62% year-over-year to $69.5 million; the trailing twelve-month figure through Mar 2026 stood at $69.5 million (up 326.62% YoY), and the FY2025 full-year result was $14.2 million, down 0.62% from the prior year.
- Equity Average for Q1 2026 stood at $69.5 million, up from $20.8 million in the prior quarter.
- The five-year high for Equity Average was $92.4 million in Q3 2023, with the low at -$30.7 million in Q1 2025.
- Average Equity Average over 5 years is $39.3 million, with a median of $41.2 million recorded in 2024.
- Peak annual rise in Equity Average reached 333.67% in 2025, while the deepest fall reached 174.39% in 2025.
- Tracing VSTM's Equity Average over 5 years: stood at $55.1 million in 2022, then climbed by 27.47% to $70.3 million in 2023, then tumbled by 112.69% to -$8.9 million in 2024, then jumped by 333.67% to $20.8 million in 2025, then soared by 233.5% to $69.5 million in 2026.
- The last three Equity Average figures came in at $69.5 million (Q1 2026), $20.8 million (Q4 2025), and $10.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn | 69.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.49 Mn |
| Dec 31, 2025 | 20.84 Mn |
| Sep 30, 2025 | 10.27 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Mar 31, 2025 | -30.66 Mn |
| Dec 31, 2024 | -8.92 Mn |
| Sep 30, 2024 | 14.96 Mn |
| Jun 30, 2024 | 21.96 Mn |
| Mar 31, 2024 | 41.22 Mn |
| Dec 31, 2023 | 70.28 Mn |
| Sep 30, 2023 | 92.39 Mn |
| Jun 30, 2023 | 67.31 Mn |
| Mar 31, 2023 | 40.21 Mn |
| Dec 31, 2022 | 55.13 Mn |
| Sep 30, 2022 | 58.38 Mn |
| Jun 30, 2022 | 63.33 Mn |
| Mar 31, 2022 | 80.17 Mn |
| Dec 31, 2021 | 91.61 Mn |
| Sep 30, 2021 | 91.93 Mn |
| Jun 30, 2021 | 95.41 Mn |
| Mar 31, 2021 | 108.94 Mn |
| Dec 31, 2020 | 122.52 Mn |
| Sep 30, 2020 | 122.07 Mn |
| Jun 30, 2020 | 118.68 Mn |
| Mar 31, 2020 | 65.08 Mn |
| Dec 31, 2019 | 14.35 Mn |
| Sep 30, 2019 | 35.41 Mn |
| Jun 30, 2019 | 68.88 Mn |
| Mar 31, 2019 | 106.38 Mn |
| Dec 31, 2018 | 115.96 Mn |
| Sep 30, 2018 | 117.24 Mn |
| Jun 30, 2018 | 82.71 Mn |
| Mar 31, 2018 | 48.12 Mn |
| Dec 31, 2017 | 49.33 Mn |
| Sep 30, 2017 | 44.61 Mn |
| Jun 30, 2017 | 54.35 Mn |
| Mar 31, 2017 | 66.38 Mn |
| Dec 31, 2016 | 77.37 Mn |
| Sep 30, 2016 | 85.75 Mn |
| Jun 30, 2016 | 92.52 Mn |
| Mar 31, 2016 | 99.22 Mn |
| Dec 31, 2015 | 107.36 Mn |
| Sep 30, 2015 | 118.75 Mn |
| Jun 30, 2015 | 128.58 Mn |
| Mar 31, 2015 | 110.34 Mn |
| Dec 31, 2014 | 88.79 Mn |
| Sep 30, 2014 | 94.00 Mn |
| Jun 30, 2014 | 104.25 Mn |
| Mar 31, 2014 | 113.39 Mn |
| Dec 31, 2013 | 122.08 Mn |
| Sep 30, 2013 | 100.70 Mn |
| Jun 30, 2013 | 78.76 Mn |
| Mar 31, 2013 | 86.65 Mn |
| Dec 31, 2012 | 93.04 Mn |
| Sep 30, 2012 | 98.99 Mn |
| Jun 30, 2012 | 105.02 Mn |
| Mar 31, 2012 | 47.45 Mn |